{
    "eid": "2-s2.0-85140207288",
    "title": "Highly efficient hybridoma generation and screening strategy for anti-PD-1 monoclonal antibody development",
    "cover-date": "2022-12-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Multidisciplinary",
            "@code": "1000",
            "@abbrev": "MULT"
        }
    ],
    "keywords": [],
    "authors": [
        "Tanapati Phakham",
        "Chatikorn Boonkrai",
        "Tossapon Wongtangprasert",
        "Thittaya Audomsun",
        "Chadaporn Attakitbancha",
        "Pijitra Saelao",
        "Phijitra Muanwien",
        "Sarintip Sooksai",
        "Nattiya Hirankarn",
        "Trairak Pisitkun"
    ],
    "citedby-count": 2,
    "ref-count": 33,
    "ref-list": [
        "Cancer immunotherapy beyond immune checkpoint inhibitors",
        "A guide to cancer immunotherapy: from T cell basic science to clinical practice",
        "The blockade of immune checkpoints in cancer immunotherapy",
        "Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors",
        "Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence",
        "Cancer immunotherapy using checkpoint blockade",
        "FDA approves 100th monoclonal antibody product",
        "Combination immunotherapy approaches",
        "The adverse events associated with combination immunotherapy in cancers: Challenges and chances",
        "Current trends in cancer immunotherapy",
        "Principles and current clinical landscape of multispecific antibodies against cancer",
        "Bispecific antibodies",
        "Enhancing CAR T cell anti-tumor efficacy through secreted single chain variable fragment (scfv) immune checkpoint blockade",
        "PD-1/PD-L1 Based combinational cancer therapy: Icing on the cake",
        "Phase Ib study of utomilumab (PF-05082566), a 4\u20131BB/CD137 agonist, in combination with pembrolizumab (MK-3475) in patients with advanced solid tumors",
        "Preclinical development of the anti-LAG-3 antibody REGN3767: Characterization and activity in combination with the Anti-PD-1 antibody cemiplimab in human PD-1xLAG-3-knockin mice",
        "Anti-PD-1 and novel combinations in the treatment of melanoma-an update",
        "Bispecific antibody simultaneously targeting PD1 and HER2 inhibits tumor growth via direct tumor cell killing in combination with PD1/PDL1 blockade and HER2 inhibition",
        "Tumor-targeting anti-EGFR x anti-PD1 bispecific antibody inhibits EGFR-overexpressing tumor growth by combining EGFR blockade and immune activation with direct tumor cell killing",
        "Design and efficacy of a monovalent bispecific PD-1/CTLA4 antibody that enhances CTLA4 blockade on PD-1(+) activated T cells",
        "Building on the anti-PD1/PD-L1 backbone: combination immunotherapy for cancer",
        "Current issues and perspectives in PD-1 blockade cancer immunotherapy",
        "Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma",
        "Antibodies to watch in 2021",
        "Mammalian cell fusion in an electroporation device",
        "An optimized electrofusion-based protocol for generating virus-specific human monoclonal antibodies",
        "Evaluation of adjuvant regimens for antibody development in rabbits (36.29)",
        "Generation of monoclonal antibodies against native viral proteins using antigen-expressing mammalian cells for mouse immunization",
        "A Comparison of intramuscular and subcutaneous administration of ligA subunit vaccine adjuvanted with neutral liposomal formulation containing monophosphoryl lipid A and QS21",
        "Impact of dose, route, and composition on the immunogenicity of immune polyelectrolyte multilayers delivered on gold templates",
        "Generation of potent mouse monoclonal antibodies to self-proteins using T-cell epitope \"tags\"",
        "Functional characterization of pembrolizumab produced in nicotiana benthamiana using a rapid transient expression system",
        "A simplified workflow for monoclonal antibody sequencing"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60199584",
            "affilname": "Chulalongkorn Cancer Immunotherapy Excellence Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199584",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Chulalongkorn University"
    ]
}